ADAR1 Takes a Stand
ADAR1 Capital Management, a significant shareholder in Keros Therapeutics, is making waves with a recent open letter directed at the company's Board of Directors. With a ownership stake of approximately 13.3%, ADAR1's position and voice carry weight as they urge the Board to engage in constructive discussions regarding strategy, capital allocation, and refreshment of the Board itself.
The Disappointment
In the letter, ADAR1 expressed their disappointment with Keros' current management strategy and engagement tactics. The firm emphasized their desire for a dialogue regarding potential strategies to maximize shareholder value, particularly in the wake of recent shareholder dissatisfaction reflected in annual meeting results.
A Call for Dialogue
It was noted that ADAR1 attempted to initiate a private conversation with the Board earlier, advocating for an in-person meeting to share their insights. However, rather than opening a dialogue, management has reportedly deflected communication, referring ADAR1 to their financial advisors. This refusal to engage directly has raised eyebrows, especially given the growing concerns among shareholders about the company's strategic direction.
Unlocking Value for Shareholders
Among the core messages in ADAR1's letter was a belief that Keros is undervalued. They argue that the company's substantial cash reserves and the net present value of its partnered assets should translate into a much higher stock price. ADAR1 is eager to collaborate with the Board to unlock this perceived value, voicing a strong intention to work together.
Immediate Concerns
Another pressing issue outlined was the lack of clarity surrounding a previously announced plan to return $375 million in excess capital to shareholders. Nearly two months after the announcement, ADAR1 called on the Board to provide an update on the process and timeline for this return, advocating for a special dividend that could directly benefit shareholders.
A Vision for Collaboration
ADAR1's preference is clear: they wish to partner with Keros' Board for the benefit of all shareholders. Should the Board continue to dismiss their offers for engagement, there are indications that ADAR1 may seek to elect new directors who are more willing to listen. They stress that such a move would not merely be a threat but a strategic step should engagement remain off the table.
Calling for Increased Responsiveness
ADAR1’s letter encapsulated a vision for the future of Keros—a future in which the Board actively listens to and collaborates with its shareholders. The message implores the Board to recognize this opportunity for strategic improvement and consider the insights that ADAR1 has to offer. With the right approach, there is potential for long-term value creation at Keros that benefits all stakeholders.
Understanding ADAR1 Capital Management
Founded in October 2018, ADAR1 Capital Management is an investment manager that specializes in public and private equity investments in the life sciences and biotechnology sectors. The firm, led by Daniel Schneeberger, is comprised of professionals with extensive backgrounds in healthcare and investment, showcasing a track record of success in biopharmaceutical investments.
Contact Information
For further engagement with ADAR1, interested parties can reach out via email at info@adar1.com or call 512-254-3790. Open communication lines are essential as Keros navigates this critical juncture.
Frequently Asked Questions
What is the purpose of ADAR1's letter to Keros' Board?
ADAR1's letter aims to foster productive dialogue regarding strategy, capital allocation, and Board refreshment, advocating for shareholder interests.
What concerns did ADAR1 express in their communication?
ADAR1 expressed disappointment at Keros' management's lack of engagement and the delay in returning excess capital to shareholders.
How does ADAR1 believe Keros is undervalued?
They argue that the company's substantial cash reserves and net present value from partnerships indicate a significantly higher value than current stock price levels.
What actions might ADAR1 pursue if the Board does not engage?
If engagement continues to be refused, ADAR1 may seek to nominate new directors at the next Annual Meeting who are willing to listen to shareholder perspectives.
Who leads ADAR1 Capital Management?
ADAR1 is led by Daniel Schneeberger, who has over 20 years of experience in the healthcare and investment sectors.
